Medpace (MEDP)
Runs integrated Phase I–IV trials and laboratory services for drug and device developers.
Something off on this page? Send us feedback.
Provides full-service Phase I–IV clinical development, laboratory, imaging, and regulatory services to biotechnology, pharmaceutical, and medical-device sponsors. Revenue follows progress on integrated contracts, while the one-segment model centralizes systems and expertise; customers can cancel or reduce scope, and delivery depends on specialized staff.
Runs outsourced Phase I–IV clinical development for biotechnology, pharmaceutical, and medical-device sponsors, combining trial execution with scientific, regulatory, imaging, central-laboratory, bioanalytical, and early-phase services. Therapeutic expertise spans oncology, metabolic disease, cardiology, central nervous system, and infectious disease.
Operates as one reportable segment through centralized systems, customer interfaces, support functions, and shared processes. Therapeutic and regulatory specialists coordinate integrated services, while an international footprint supports sponsors across dozens of countries.
Recognizes revenue as contract services progress, with most clinical-research contracts treated as a single performance obligation because the services are integrated. Customers can cancel or reduce scope, backlog may not convert at historical rates, and delivery depends on retaining senior leaders and qualified scientific, medical, technical, and operating staff.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 24, 2026 | RBC Capital | Reiterate | Rating: —Target: $484 | Target: $692 |
| Jul 24, 2026 | Mizuho Securities | Target | Target: $586 | Target: $665 |
| Jul 24, 2026 | BMO Capital | Reiterate | Rating: —Target: $400 | Target: $600 |
| Jul 24, 2026 | Robert W. Baird | Target | Target: $547 | Target: $624 |
| Jul 23, 2026 | Barclays | Target | Target: $450 | Target: $600 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $502.7M · Total debt $120.1M · Total assets $2.06B · Shareholders' equity $433.9M
- Revenue
- $707.3M
- Operating income
- $146.8M
- Net income
- $121.4M
No dividends on record.
| Institutions | 89.81% | 25.07M shares | |
|---|---|---|---|
| 712 holders · as of Jun 30, 2026 | |||
| Insiders | 20.41% | 5.70M shares | |
| 10 holders · as of Sep 21, 2026 | |||
| Adds to | 110.22% | ||
27.91M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 110.22%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
August J. Troendle1Insiderdirector, 10 percent owner, officer: President & CEO | 19.83% | 5.68M | filed Sep 21, 2026 |
BlackRock, Inc.Institution | 8.95% | 2.50M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 7.42% | 2.07M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 4.58% | 1.28M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.06% | 1.13M | as of Jun 30, 2026 |
- August J. Troendle's transaction reports restate only vehicles that traded; the 2025 ownership statement (5.68M) less the 148.3K net shares sold since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | August J. Troendle | director, 10 percent owner, officer: President & CEO | −10,880 | $620.40 |
| Sep 16, 2026 | August J. Troendle | director, 10 percent owner, officer: President & CEO | −8,770 | $621.29 |
| Sep 15, 2026 | August J. Troendle | director, 10 percent owner, officer: President & CEO | −15,971 | $620.84 |
| Aug 27, 2026 | August J. Troendle | director, 10 percent owner, officer: President & CEO | −650 | $620.27 |
| Aug 26, 2026 | Robert O. Kraft | director | −3,858 | $617.81 |
- IQVIA
Broad rival in global Phase I-IV clinical development and trial operations
- ICON
Full-service CRO rival across clinical development and biotech outsourcing
- Thermo Fisher Scientific
PPD-led rival in integrated clinical development and analytical services
- Fortrea
Focused CRO rival in trial management, clinical pharmacology, and consulting
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Medpace | $621.75 | −0.39% | $17.42B | 36.6 | 33.8 | 6.3 | +17.2% |
| IQVIA | $269.37 | −0.19% | $44.42B | 33.5 | 19.8 | 2.6 | +8.7% |
| ICON | $169.05 | −0.30% | $12.98B | 39.8 | 15.2 | 1.6 | +2.3% |
| Thermo Fisher Scientific | $658.10 | −0.10% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Fortrea | $20.30 | +1.37% | $1.90B | — | 21.1 | 0.7 | −4.5% |
| Median | 35.4 | 20.4 | 2.1 | +5.5% |